MYC is amplified in approximately 15 % of breast cancers and is associated with poor outcome. c-MYC protein is multi-faceted and involved in many aspects of cell functions like replication, growth metabolism, differentiation and apoptosis and is linked with therapeutic response in breast cancer. The mechanisms of c-MYC action in controlling these different roles remains poorly understood. Materials and methods: A cross sectional study involving 45 cases of breast cancer were studied for amplification of c-Myc gene by FISH. FISH signal images were recorded using a Leica fluorescent microscope equipped with a camera and multiple fluorescence filter sets comprising three color filter sets DAPI, red, and green. Total number of signals were counted in 100 cells. The normal control ratio was 2:2; any increase in the ratio was considered as a gene amplification. The results were reported as the amount of MYC signals divided by the number of centromere signals of chromosome 8(MYC: CEP8). Results: Out of 45 cases of breast carcinoma, amplification of c-Myc gene was noted in 20 cases (44 %). The percentage of cases with gene gains of three copies or higher was 20 % (9 out of 45), with a highest index of 10 to 12 signals per nucleus. Conclusion: MYC gene amplification is critical in the etiology of breast cancer, leading to tumor aggressiveness and treatment resistance. Understanding the molecular mechanisms behind MYC amplification and its clinical implications is critical for developing novel therapeutic methods that target MYC-driven oncogenesis. Identification of MYC target genes is essential in isolating signaling pathways that drive tumor development.